Westley B, May F E, Brown A M, Krust A, Chambon P, Lippman M E, Rochefort H
J Biol Chem. 1984 Aug 25;259(16):10030-5.
The effects of estradiol and antiestrogens on two estrogen-regulated proteins (52 and 160 kDa) and an estrogen-inducible mRNA (pS2) have been measured in the MCF7 human breast cancer cell line and two tamoxifen-resistant sublines. In MCF7 cells, tamoxifen (or nafoxidine) alone does not significantly affect pS2 mRNA levels nor transcription of the pS2 gene but completely antagonizes the ability of estradiol to increase pS2 RNA levels. The estrogen-mediated increase in pS2 mRNA levels resembles that of two estrogen-regulated proteins (52 and 160 kDa) that are released from MCF7 cells into the culture medium. This is distinct from the estrogen-mediated increase in progesterone receptor which is also obtained by tamoxifen treatment. In the two tamoxifen-resistant sublines (R27 and RTx6), tamoxifen does not increase pS2 mRNA levels or 160-kDa protein production but increases the production of the 52-kDa protein. These results show that in these tamoxifen-resistant cells, tamoxifen has become fully estrogenic for one, but not all estrogen-regulated responses.
在MCF7人乳腺癌细胞系及两个他莫昔芬耐药亚系中,已检测了雌二醇和抗雌激素对两种雌激素调节蛋白(52 kDa和160 kDa)以及一种雌激素诱导型mRNA(pS2)的影响。在MCF7细胞中,单独使用他莫昔芬(或奈法唑酮)不会显著影响pS2 mRNA水平或pS2基因的转录,但会完全拮抗雌二醇增加pS2 RNA水平的能力。雌激素介导的pS2 mRNA水平增加类似于两种从MCF7细胞释放到培养基中的雌激素调节蛋白(52 kDa和160 kDa)的增加情况。这与他莫昔芬治疗也能获得的雌激素介导的孕酮受体增加不同。在两个他莫昔芬耐药亚系(R27和RTX6)中,他莫昔芬不会增加pS2 mRNA水平或160 kDa蛋白的产生,但会增加52 kDa蛋白的产生。这些结果表明,在这些他莫昔芬耐药细胞中,他莫昔芬对一种而非所有雌激素调节反应已完全具有雌激素样作用。